Denali Therapeutics Inc. (DNLI)
DNLI Stock Price Chart
Explore Denali Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze DNLI price movements and trends.
DNLI Company Profile
Discover essential business fundamentals and corporate details for Denali Therapeutics Inc. (DNLI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Dec 2017
Employees
443.00
CEO
Ryan J. Watts
Description
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
DNLI Financial Timeline
Browse a chronological timeline of Denali Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.72, while revenue estimate is $2.15m.
Earnings released on 7 May 2026
EPS came in at -$0.69 surpassing the estimated -$0.73 by +5.48%.
Earnings released on 26 Feb 2026
EPS came in at -$0.73 surpassing the estimated -$0.75 by +2.67%.
Earnings released on 6 Nov 2025
EPS came in at -$0.74 surpassing the estimated -$0.76 by +2.63%.
Earnings released on 11 Aug 2025
EPS came in at -$0.72 surpassing the estimated -$0.74 by +2.70%.
Earnings released on 6 May 2025
EPS came in at -$0.78 falling short of the estimated -$0.71 by -9.86%.
Earnings released on 27 Feb 2025
EPS came in at -$0.67 surpassing the estimated -$0.75 by +10.67%.
Earnings released on 6 Nov 2024
EPS came in at -$0.63 falling short of the estimated -$0.60 by -5.00%.
Earnings released on 1 Aug 2024
EPS came in at -$0.59 surpassing the estimated -$0.68 by +13.24%.
Earnings released on 7 May 2024
EPS came in at -$0.68 falling short of the estimated -$0.67 by -1.49%.
Earnings released on 27 Feb 2024
EPS came in at -$0.86 falling short of the estimated -$0.82 by -4.88%, while revenue for the quarter reached $305.04m , beating expectations by +3.55k%.
Earnings released on 7 Nov 2023
EPS came in at -$0.72 surpassing the estimated -$0.83 by +13.25%, while revenue for the quarter reached $1.27m , missing expectations by -85.83%.
Earnings released on 8 Aug 2023
EPS came in at $1.30 surpassing the estimated -$0.68 by +291.18%, while revenue for the quarter reached $294.12m , beating expectations by +2.09k%.
Earnings released on 8 May 2023
EPS came in at -$0.80 falling short of the estimated -$0.71 by -12.68%, while revenue for the quarter reached $35.14m , beating expectations by +22.34%.
Earnings released on 27 Feb 2023
EPS came in at -$0.75 surpassing the estimated -$0.78 by +3.85%, while revenue for the quarter reached $10.28m , missing expectations by -21.60%.
Earnings released on 3 Nov 2022
EPS came in at -$0.84 falling short of the estimated -$0.83 by -1.20%, while revenue for the quarter reached $3.56m , missing expectations by -79.09%.
Earnings released on 8 Aug 2022
EPS came in at -$0.48 surpassing the estimated -$0.52 by +7.69%, while revenue for the quarter reached $52.48m , beating expectations by +17.52%.
Earnings released on 5 May 2022
EPS came in at -$0.53 falling short of the estimated -$0.47 by -12.77%, while revenue for the quarter reached $42.14m , beating expectations by +26.32%.
Earnings released on 28 Feb 2022
EPS came in at -$0.62 falling short of the estimated -$0.41 by -51.22%, while revenue for the quarter reached $12.51m , missing expectations by -72.08%.
Earnings released on 4 Nov 2021
EPS came in at -$0.69 falling short of the estimated -$0.51 by -35.29%, while revenue for the quarter reached $5.29m , missing expectations by -83.50%.
Earnings released on 4 Aug 2021
EPS came in at -$0.50 falling short of the estimated -$0.37 by -35.14%, while revenue for the quarter reached $22.94m , meeting expectations.
DNLI Stock Performance
Access detailed DNLI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
